Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE

TOMOX-HAIC

Oxaliplatin 85mg/m\^2 plus Raltitrexed 3mg/m\^2, 21 days for a cycle

DRUG

Sintilimab

200mg, ivgtt, d1, 21 days for a cycle

DRUG

Bevacizumab

7.5mg/kg, ivgtt, d1, 21 days for a cycle

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER